<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00810004</url>
  </required_header>
  <id_info>
    <org_study_id>FERGI-MAIN</org_study_id>
    <nct_id>NCT00810004</nct_id>
  </id_info>
  <brief_title>Maintenance Treatment of Iron Deficiency in IBD Patients</brief_title>
  <acronym>FER-IBD-MAIN</acronym>
  <official_title>A Multi-centre, Randomised, Prospective, Single-blinded, Controlled Study to Investigate the Efficacy and Safety of a Standardised Maintenance Dosage Regimen of Intravenous Ferric Carboxymaltose (FERINJECT®) Versus Placebo in Patients With Iron Deficiency Caused by Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vifor Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vifor Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the treatment of iron deficiency in IBD patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of maintenance treatment of iron deficiency</measure>
    <time_frame>8 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">245</enrollment>
  <condition>Iron Deficiency</condition>
  <condition>Inflammatory Bowel Disease</condition>
  <arm_group>
    <arm_group_label>Ferinject</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion of iron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NaCL 0,9%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferinject</intervention_name>
    <description>Intravenous infusion of iron</description>
    <arm_group_label>Ferinject</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Non-anaemic patients treated in the FERGI-CORRECTION study (Hb ≥12 g/dL female, ≥13 g/dL
        male), independent of ferritin value.

        Females of child-bearing potential must have a negative urine pregnancy test at screening
        and be practising an acceptable method of birth control during the study and for up to 1
        month after the last dose of study medication.

        Exclusion Criteria:

        Chronic alcohol abuse (alcohol consumption &gt;20 g/day).

        Presence of portal hypertension with oesophageal varices. History of erythropoietin,
        intravenous or oral iron therapy, or blood transfusion in 12 weeks prior to screening.

        Known hypersensitivity to FERINJECT®.

        History of acquired iron overload.

        Myelodysplastic syndrome.

        Pregnancy or lactation.

        Known active infection, clinically significant overt bleeding, active malignancy. Known
        chronic renal failure.

        Surgery with relevant blood loss (defined as Hb drop &lt;2 g/dL) in the 3 months prior to
        screening or planned surgery within the following 3 months.

        Chronic liver disease or increase of liver enzymes (alanine aminotransferase ([ALT],
        aspartate aminotransferase [AST]) &gt;3 times the upper limit of normal range.

        Known human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS),
        hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.

        Inability to fully comprehend and/or perform study procedures in the investigator's
        opinion.

        Participation in any other interventional study (except correction study) within 1 month
        prior to screening.

        Body weight &lt;35 kg.

        Significant cardiovascular disease, including myocardial infarction within 12 months prior
        to study inclusion, congestive heart failure NYHA (New York Heart Association) grade III or
        IV, or poorly controlled hypertension according to the judgment of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Gasche, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>State Scientific Center of Coloproctology of RosMedTekhnolgy</name>
      <address>
        <city>Moscow</city>
        <zip>123423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2008</study_first_submitted>
  <study_first_submitted_qc>December 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2008</study_first_posted>
  <last_update_submitted>December 19, 2012</last_update_submitted>
  <last_update_submitted_qc>December 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

